<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33632084</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-1328</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurological research</Title><ISOAbbreviation>Neurol Res</ISOAbbreviation></Journal><ArticleTitle>Overview of stem cells therapy in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>616</StartPage><EndPage>632</EndPage><MedlinePgn>616-632</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/01616412.2021.1893564</ELocationID><Abstract><AbstractText><b>Background:</b> Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. <b>Methods &amp; Results:</b> Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. <b>Conclusion:</b> The determination of whether stem cells offer a&#xa0;viable treatment strategy for ALS rests on well-designed&#xa0;and appropriately powered future clinical trials. Randomized, double-blinded,&#xa0;and sham-controlled&#xa0;studies would be valuable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Je</LastName><ForeName>Goun</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1861-6714</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keyhanian</LastName><ForeName>Kiandokht</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1384-9826</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurol Res</MedlineTA><NlmUniqueID>7905298</NlmUniqueID><ISSNLinking>0161-6412</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">als</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">stem cell therapy</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>26</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33632084</ArticleId><ArticleId IdType="doi">10.1080/01616412.2021.1893564</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>